Sequential targeting of YAP1 and p21 enhances the elimination of senescent cells induced by the BET inhibitor JQ1
Abstract Chondrosarcoma (CHS) is the second most common bone malignancy with limited therapeutic approaches. Our previous study has found that Yes associated protein 1 (YAP1) is downregulated in CHS cells treated with bromodomain and extraterminal domain (BET) inhibitor JQ1. However, the precise rol...
Main Authors: | Huan-Tian Zhang, Tao Gui, Ri-Xu Liu, Kui-Leung Tong, Chong-Jie Wu, Zhenyan Li, Xun Huang, Qiu-Tong Xu, Jie Yang, Wang Tang, Yuan Sang, Wanting Liu, Ning Liu, Ryan D. Ross, Qing-Yu He, Zhen-Gang Zha |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-01-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-021-03416-1 |
Similar Items
-
Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer
by: Luan W, et al.
Published: (2019-10-01) -
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
by: Aubrey L. Miller, et al.
Published: (2021-07-01) -
Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer [Corrigendum]
by: Luan W, et al.
Published: (2019-11-01) -
Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice
by: Kedaigle, Amanda J, et al.
Published: (2020) -
Nanoparticles Loaded with the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells In Vitro and In Vivo
by: Valentina Maggisano, et al.
Published: (2019-12-01)